1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Summary

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells

Scope

- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Remicade including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Remicade for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Remicade performance
- Obtain sales forecast for Remicade from 2012-2022 in the top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India)

Table Of Contents

Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.2 Symptoms 16
3.2.1 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.1.3 Clinical Practice 23
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
6 Remicade (infliximab) 30
6.1 Overview 30
6.2 Efficacy 32
6.3 Safety 33
6.4 SWOT Analysis 34
6.5 Forecast 37
7 Appendix 38
7.1 Bibliography 38
7.2 Abbreviations 40
7.3 Methodology 43
7.4 Forecasting Methodology 43
7.4.1 Diagnosed UC Patients 43
7.4.2 Percent Drug-Treated Patients 44
7.4.3 General Pricing Assumptions 44
7.4.4 Individual Drug Assumptions 45
7.4.5 Generic Erosion 45
7.5 Physicians and Specialists Included in This Study 46
7.6 Primary Research - Prescriber Survey 47
7.7 About the Authors 48
7.7.1 Author 48
7.7.2 Global Head of Healthcare 49
7.8 About GlobalData 50
7.9 Disclaimer 50

1.1 List of Tables

Table 1: Genetic Factors That Confer a Predisposition to UC 14
Table 2: Typical Symptoms of UC 16
Table 3: Truelove and Witts UC Severity Index 20
Table 4: UCDAI 21
Table 5: Treatment Guidelines for UC Used in the 10MM 22
Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 23
Table 7: Leading Treatments for UC, 2014 29
Table 8: Product Profile - Remicade 32
Table 9: Remicade SWOT Analysis, 2014 36
Table 10: Global Sales Forecasts ($m) for Remicade, 2012-2022 37
Table 11: Physicians Surveyed, By Country 47

1.2 List of Figures

Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 16
Figure 2: UC Disease Management Flowchart 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.